NEW YORK, Oct. 26, 2012 /PRNewswire/ -- Griffin Securities announced today that the second part of its two-part interview series with Alan Shortall, CEO of Unilife Corporation ("Unilife") (NASDAQ: UNIS ; ASX: UNS) is now available, during which Mr. Shortall discusses Unilife's device platforms and new commercial opportunities. The interview was conducted by Dr. Keith Markey, the Scientific Director of Griffin's research division.
Both videos from the two-part series and the associated transcripts are now available on the Unilife website at www.unilife.com . The videos are also available on YouTube: video 1: http://youtu.be/X-LbVnzk1W0 ; and video 2: http://youtu.be/tDTeWn6UJLQ .
For Griffin Securities' reports on Unilife Corporation, including full disclosure statements, please contact Dr. Keith Markey at 212-514-7914 or via email, firstname.lastname@example.org .
About Unilife Corporation
Unilife Corporation (NASDAQ: UNIS  / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including dru